Moreover, in vitro down-regulation of BIRC5 gene, which encodes survivin, leads to increased chemo-sensitivity, and a clinical trial targeting BIRC5 with a novel survivin messenger ribonucleic acid (mRNA) antagonist was developed for pediatric patients with relapses of B-ALL (NCT01186328) [106]. Here, BIRC5 is linked to acute lymphoblastic leukemia.